Contraindicated. Coadministration of doravirine with a solid CYP3A inducer may lessen doravirine plasma concentrations and/or effects. Prospective for lack of virologic response and doable resistance to doravirine.pentobarbital will minimize the extent or effect of armodafinil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignifican